CN102488686A - Compound a-keto acid tablet and preparation processes thereof - Google Patents
Compound a-keto acid tablet and preparation processes thereof Download PDFInfo
- Publication number
- CN102488686A CN102488686A CN2011104371473A CN201110437147A CN102488686A CN 102488686 A CN102488686 A CN 102488686A CN 2011104371473 A CN2011104371473 A CN 2011104371473A CN 201110437147 A CN201110437147 A CN 201110437147A CN 102488686 A CN102488686 A CN 102488686A
- Authority
- CN
- China
- Prior art keywords
- mass fraction
- calcium
- keto
- coating
- mixing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a compound a-keto acid tablet and preparation processes thereof. One of the preparation processes comprises the following steps of respectively mixing and granulating slightly alkaline medicines and slightly acidic medicines, mixing the slightly alkaline medicines and the slightly acidic medicines together and carrying out tabletting and coating, and the process enables dissolubility of the compound a-keto acid tablet to be enhanced and stability of the medicines to be improved. The other of the preparation processes comprises the following steps of granulating calcium 3-methyl-2-oxovalerate and ketoleucine calcium under a dark condition, respectively granulating other slightly alkaline medicines and slightly acidic medicines, mixing all the medicines together and carrying out tabletting and coating, and the process enables dissolubility of the compound a-keto acid tablet and stability of the medicines to be further improved.
Description
Technical field
The invention belongs to field of pharmaceutical preparations, relate to a kind of compound recipe a-keto acid sheet and preparation technology thereof.
Background technology
Social in modern times, the chronic renal disease sickness rate raises day by day, and chronic renal disease finally can worsen into uremia greatly.The medicine of treatment chronic renal disease receives people's extensive concern.
Compound recipe a-keto acid sheet is a kind of medicine of good treatment chronic renal disease.Compound recipe a-keto acid sheet can replenish compound alpha-ketoacid and essential amino acids, and it is disorderly to improve vivo acid and Proteometabolism, promotes albumen synthetic; Cooperate low protein diet, the height that alleviates glomerule filters, and the protection nephron slows down chronic renal failure and worsens.
It is found that in practical application this disintegration of tablet speed is slower, drug dissolution is low.The people of pharmacy knows: drug dissolution is low, often makes medicine low in absorption by human body, influences the therapeutic effect of medicine, and simultaneously, this tablet is the compound preparation of multiple medicine, and stability of drug is undesirable.
Summary of the invention
The object of the invention is exactly the defective to prior art, and a kind of compound recipe a-keto acid sheet and new preparation process thereof are provided, and it is on the low side to solve compound recipe a-keto acid sheet drug dissolution, the difficult problem that stability of drug is bad.
We find: during the medicine of compound recipe a-keto acid sheet was formed, some medicine meta-alkalescence was like keto-valine calcium, racemic ketoprofen isoleucine calcium, keto-leucine calcium, racemization hydroxyl Methionine calcium salt., Phenylalanine calcium salt., lysine acetate, histidine; Some medicine slant acidity is like threonine, tryptophan, tyrosine.The disclosed preparation technology of compound recipe a-ketonic acid preparation always mixes granulation, tabletting with above-mentioned meta-alkalescence and slant acidity medicine.
We find pleasantly surprisedly: with meta-alkalescence medicine and slant acidity medicine difference mixing granulation, and then mix, and tabletting, the result is the dissolution that has improved compound recipe a-keto acid sheet greatly, its beneficial effect is seen embodiment 2.
We also find: with meta-alkalescence medicine and slant acidity medicine difference mixing granulation, also improved stability of drug.Its beneficial effect is seen embodiment 3.
Its reason possibly be: mixing granulation is granulated relatively with total mixing respectively, and its basic group and acidic-group touch opportunity are less, have reduced the adhesion between them, and is useful to improving dissolution,
Mixing granulation has respectively avoided alkalescent medicine and acidic drug to mix, produce impurity in the heating process granulating, and behind total mixed pressure sheet, minimizing contacts, and helps improving stability of drug.
We also find through overtesting: racemic ketoprofen isoleucine calcium, keto-leucine calcium to its independent granulation, are granulated to keto-valine calcium, racemization hydroxyl Methionine calcium salt. ketone, Phenylalanine calcium salt., lysine acetate, histidine respectively under the lucifuge condition to photo-labile; Threonine, tryptophan, tyrosine are granulated, and 3 kinds of total mixed pressure sheets of granule are not only useful to improving dissolution then, and improve its beneficial effect of stability of drug greatly and see embodiment 3
We have invented compound recipe a-keto acid sheet, and its label is made up of the raw material and the adjuvant of following mass fraction:
Keto-valine calcium 86
Racemic ketoprofen isoleucine calcium 67
Keto-leucine calcium 101
Racemization hydroxyl Methionine calcium salt. 59
Ketone Phenylalanine calcium salt. 68
Lysine acetate 105
Histidine 38
Threonine 53
Tryptophan 23
Tyrosine 30
Starch 35-45
Cross-linked pvp 35-45
PVP 33
Pulvis Talci 10-12
Magnesium stearate 8-10
Compound recipe a-keto acid sheet, one of preparation technology:
Be characterized in: method for preparing is that the meta-alkalescence medicine is keto-valine calcium, racemic ketoprofen isoleucine calcium, keto-leucine calcium, racemization hydroxyl Methionine calcium salt., Phenylalanine calcium salt., lysine acetate, histidine with meta-alkalescence medicine and slant acidity medicine difference mixing granulation; The slant acidity medicine is threonine, tryptophan, tyrosine.Preparation technology is following in detail:
1) above-mentioned mass fraction supplementary material is crossed 80 mesh sieves respectively;
2) with above-mentioned mass fraction keto-valine calcium, racemic ketoprofen isoleucine calcium, keto-leucine calcium, racemization hydroxyl Methionine calcium salt., Phenylalanine calcium salt., lysine acetate, histidine mixing; Add the starch of mass fraction 25-30, the cross-linked pvp of mass fraction 30-35; Further mixing gets mixture;
The PVP of mass fraction 28 is joined in the 360ml isopropyl alcohol, stir, after stirring, join in the said mixture, 20 orders are granulated, 70 ℃ of forced air dryings 2 hours, granule 1;
3) with above-mentioned mass fraction threonine, tryptophan, tyrosine mixing, add the starch of mass fraction 10-15, the cross-linked pvp of mass fraction 5-10, further mixing gets mixture;
The PVP of mass fraction 5 is joined in the 64ml isopropyl alcohol, stir, after stirring, join in the said mixture, 20 orders are granulated, 70 ℃ of forced air dryings 2 hours, granule 2;
4) granule 1,2 is mixed after, add mass fraction 10-12 Pulvis Talci, add the magnesium stearate of mass fraction 8-10, mixed pressuring plate, 60 ℃ of forced air dryings 2 hours, label;
5) tabletting: heavy according to the actual sheet of result of calculation gained, regulate sheet and weigh tabletting.
6) coating: the stomach dissolution type Opadry of mass fraction 7 is dissolved in 80% ethanol of mass fraction 93, makes coating solution, in coating pan, label is carried out coating, 60 ℃ of forced air drying half an hour, label increases weight about 3% behind the coating behind the coating.
7) detect qualified after, packing.
80% ethanol: ethanol for moisture 20%
Compound recipe a-keto acid sheet, preparation technology's two:
Be characterized in: method for preparing is with racemic ketoprofen isoleucine calcium, keto-leucine calcium mixing granulation under the lucifuge condition, racemization hydroxyl Methionine calcium salt., Phenylalanine calcium salt., lysine acetate, histidine mixing granulation, threonine, tryptophan, tyrosine mixing granulation.Preparation technology is following in detail:
1) above-mentioned mass fraction supplementary material is crossed 80 mesh sieves respectively;
2) under the lucifuge condition, with above-mentioned mass fraction racemic ketoprofen isoleucine calcium, keto-leucine calcium mixing, add the starch of mass fraction 8-10, the cross-linked pvp of mass fraction 10-12, further mixing gets mixture;
The PVP of mass fraction 9.3 is joined in the 120ml isopropyl alcohol, stir, after stirring, join in the said mixture, 20 orders are granulated, 70 ℃ of forced air dryings 2 hours, granule 1, whole technical process requires lucifuge;
3) with above-mentioned mass fraction keto-valine calcium, racemization hydroxyl Methionine calcium salt., Phenylalanine calcium salt., lysine acetate, histidine mixing, add the starch of mass fraction 17-20, the cross-linked pvp of mass fraction 20-23, further mixing gets mixture;
The PVP of mass fraction 18.7 is joined in the 240ml isopropyl alcohol, stir, after stirring, join in the said mixture, 20 orders are granulated, 70 ℃ of forced air dryings 2 hours, granule 2;
4) with above-mentioned mass fraction threonine, tryptophan, tyrosine mixing, add the starch of mass fraction 10-15, the cross-linked pvp of mass fraction 5-10, further mixing gets mixture;
The PVP of mass fraction 5 is joined in the 64ml isopropyl alcohol, stir, after stirring, join in the said mixture, 20 orders are granulated, 70 ℃ of forced air dryings 2 hours, granule 3;
5) granule 1,2,3 is mixed after, add mass fraction 10-12 Pulvis Talci, add the magnesium stearate of mass fraction 8-10, mixed pressuring plate, 60 ℃ of forced air dryings 2 hours, label, heavy according to the actual sheet of result of calculation gained, regulate sheet and weigh tabletting;
6) coating: the stomach dissolution type Opadry of mass fraction 7 is dissolved in 80% ethanol of mass fraction 93, makes coating solution, in coating pan, label is carried out coating, 60 ℃ of forced air drying half an hour, label increases weight about 3% behind the coating behind the coating;
7) detect qualified after, packing.
The specific embodiment
Following embodiment is used for further narrating the present invention, but does not do any restriction.
1 of the preparation of embodiment 1 compound recipe a-keto acid sheet
Prescription: (1000)
Keto-valine calcium 86g
Racemic ketoprofen isoleucine calcium 67g
Keto-leucine calcium 101g
Racemization hydroxyl Methionine calcium salt. 59g
Ketone Phenylalanine calcium salt. 68g
Lysine acetate 105g
Histidine 38g
Threonine 53g
Tryptophan 23g
Tyrosine 30g
Starch 40g
Cross-linked pvp 40g
PVP 33g
Pulvis Talci 10g
Magnesium stearate 8g
Preparation technology:
1) above-mentioned mass fraction supplementary material is crossed 80 mesh sieves respectively;
2) with above-mentioned mass fraction keto-valine calcium, racemic ketoprofen isoleucine calcium, keto-leucine calcium, racemization hydroxyl Methionine calcium salt., Phenylalanine calcium salt., lysine acetate, histidine mixing, add the cross-linked pvp of 30g starch, 35g, further mixing gets mixture;
The PVP of 28g joins in the 360ml isopropyl alcohol, stirs, and after stirring, joins in the said mixture, and 20 orders are granulated, 70 ℃ of forced air dryings 2 hours, granule 1;
3) with above-mentioned mass fraction threonine, tryptophan, tyrosine mixing, add the starch of 10g, the cross-linked pvp of 5g, further mixing gets mixture;
The PVP of 5g is joined in the 64ml isopropyl alcohol, stir, after stirring, join in the said mixture, 20 orders are granulated, 70 ℃ of forced air dryings 2 hours, granule 2;
4) granule 1,2 is mixed after, add mass fraction 10g Pulvis Talci, add the magnesium stearate of 8g, mixed pressuring plate, 60 ℃ of forced air dryings 2 hours, label; Heavy according to the actual sheet of result of calculation gained, regulate sheet and weigh tabletting.
5) coating: the stomach dissolution type Opadry of mass fraction 7 is dissolved in 80% ethanol of mass fraction 93, makes coating solution, in coating pan, label is carried out coating, 60 ℃ of forced air drying half an hour, label increases weight about 3% behind the coating behind the coating.
6) detect qualified after, packing.
2 of the preparation of embodiment 2 compound recipe a-keto acid sheets
Prescription: (1000)
Keto-valine calcium 86g
Racemic ketoprofen isoleucine calcium 67g
Keto-leucine calcium 101g
Racemization hydroxyl Methionine calcium salt. 59g
Ketone Phenylalanine calcium salt. 68g
Lysine acetate 105g
Tyrosine 30g
Histidine 38g
Threonine 53g
Tryptophan 23g
Tyrosine 30g
Starch 40g
Cross-linked pvp 40g
PVP 33g
Pulvis Talci 10g
Magnesium stearate 8g
Preparation technology:
1) above-mentioned mass fraction supplementary material is crossed 80 mesh sieves respectively;
2) under the lucifuge condition, with racemic ketoprofen isoleucine calcium 67g, keto-leucine calcium 101g mixing, add 10 g starch, 12 g cross-linked pvps, further mixing gets mixture;
9.3gPVP is joined in the 120ml isopropyl alcohol, stir, after stirring, join in the said mixture, 20 orders are granulated, 70 ℃ of forced air dryings 2 hours, granule 1, whole technical process requires lucifuge;
3) with keto-valine calcium 86g, racemization hydroxyl Methionine calcium salt. 59g, Phenylalanine calcium salt. 68g, lysine acetate 105g, histidine 38g mixing, add 20g starch, 20g cross-linked pvp, further mixing gets mixture;
18.7gPVP is joined in the 240ml isopropyl alcohol, stir, after stirring, join in the said mixture, 20 orders are granulated, 70 ℃ of forced air dryings 2 hours, granule 2;
4) with threonine 53g, tryptophan 23g, tyrosine 30g mixing, add 10g starch, 8g cross-linked pvp, further mixing gets mixture;
5gPVP is joined in the 64ml isopropyl alcohol, stir, after stirring, join in the said mixture, 20 orders are granulated, 70 ℃ of forced air dryings 2 hours, granule 3;
5) granule 1,2,3 is mixed after, add 10g Pulvis Talci, add mass fraction 8g magnesium stearate, mixed pressuring plate, 60 ℃ of forced air dryings 2 hours, label, heavy according to the actual sheet of result of calculation gained, regulate sheet and weigh tabletting;
6) coating: the stomach dissolution type Opadry of mass fraction 7 is dissolved in 80% ethanol of mass fraction 93, makes coating solution, in coating pan, label is carried out coating, 60 ℃ of forced air drying half an hour, label increases weight about 3% behind the coating behind the coating;
7) detect qualified after, packing.
The comparative study of embodiment 3 compound recipe a-keto acid sheets
1, we obtain the A sample according to embodiment 1 prescription, prepared compound recipe a-keto acid sheet.
2, we are according to embodiment 1 prescription, and technology obtains the B sample according to total mode of granulating of mixing, and its preparation technology is following:
1) above-mentioned mass fraction supplementary material is crossed 80 mesh sieves respectively;
2) with the above-mentioned keto-valine calcium that sieves, racemic ketoprofen isoleucine calcium, keto-leucine calcium, racemization hydroxyl Methionine calcium salt. ketone, Phenylalanine calcium salt., lysine acetate, histidine, threonine, tryptophan, tyrosine mixing; The cross-linked pvp that adds 40g starch, 40g; Further mixing gets mixture;
The PVP of 33g joins in the 424ml isopropyl alcohol, stirs, and after stirring, joins in the said mixture, and 20 orders are granulated, 70 ℃ of forced air dryings 2 hours, granule;
3) with granule add mass fraction 10g Pulvis Talci, add the magnesium stearate of 8g, mixed pressuring plate, 60 ℃ of forced air dryings 2 hours, label; Heavy according to the actual sheet of result of calculation gained, regulate sheet and weigh tabletting.
4) coating: the stomach dissolution type Opadry of mass fraction 7 is dissolved in 80% ethanol of mass fraction 93, makes coating solution, in coating pan, label is carried out coating, 60 ℃ of forced air drying half an hour, label increases weight about 3% behind the coating behind the coating.
3, we obtain the C sample according to embodiment 2 prescriptions, prepared compound recipe a-keto acid sheet.
4, to A, B, C sample carry out the dissolution comparative test simultaneously
According to the method for Chinese Pharmacopoeia version regulation in 2010, in simulated gastric fluid (0.1mol/L hydrochloric acid solution), result of the test is seen table 1:
| Sample | Dissolution (meansigma methods) |
| Sample A | ８8％ |
| Sample B | 76％ |
| Sample C | 9５％ |
Can find out from last table: with meta-alkalescence medicine and slant acidity medicine difference mixing granulation; And then mix, tabletting, the result is the dissolution that has improved compound recipe a-keto acid sheet; With racemic ketoprofen isoleucine calcium, keto-leucine calcium mixing granulation under the lucifuge condition; Racemization hydroxyl Methionine calcium salt., Phenylalanine calcium salt., lysine acetate, histidine mixing granulation, the mode of threonine, tryptophan, tyrosine mixing granulation, the dissolution of compound recipe a-keto acid sheet is best.
5, to A, the B sample carries out the long-time stability comparative test simultaneously:
The long term test condition
:Sample is put in the carton and is deposited, and is placed in the stability test case, and condition is 25 ± 2 ℃ of humidity RH60 ± 5% of temperature, and commercially available back is placed.
Long term test: 0 month, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months. to A, the B sample carries out the long-time stability comparative test simultaneously, the variation of its its related substances (%)
See the following form:
| Sample | 0 month | 3 months | 6 months | 9 months | 12 months | 18 months |
| A | 0.27 | 0.29 | 0.31 | 0.39 | 0.43 | 0.49 |
| B | 0.35 | 0.44 | 0.48 | 0.58 | 0.65 | 0.85 |
| C | 0.19 | 0.21 | 0.25 | 0.29 | 0.33 | 0.39 |
Can find out from last table: with meta-alkalescence medicine and slant acidity medicine difference mixing granulation, and then mix, tabletting, the result is that its related substances reduces, and has improved stability of drug.
With racemic ketoprofen isoleucine calcium, keto-leucine calcium mixing granulation under the lucifuge condition; Racemization hydroxyl Methionine calcium salt., Phenylalanine calcium salt., lysine acetate, histidine mixing granulation; The mode of threonine, tryptophan, tyrosine mixing granulation, stability of drug is best.
Claims (5)
1. compound recipe a-keto acid sheet is characterized in that its label is made up of the raw material and the adjuvant of following mass fraction:
Keto-valine calcium 86
Racemic ketoprofen isoleucine calcium 67
Keto-leucine calcium 101
Racemization hydroxyl Methionine calcium salt. 59
Ketone Phenylalanine calcium salt. 68
Lysine acetate 105
Histidine 38
Threonine 53
Tryptophan 23
Tyrosine 30
Starch 35-45
Cross-linked pvp 35-45
PVP 33
Pulvis Talci 10-12
Magnesium stearate 8-10.
2. compound recipe a-keto acid sheet according to claim 1; It is characterized in that: method for preparing is that meta-alkalescence medicine and slant acidity medicine are granulated respectively, and the meta-alkalescence medicine is keto-valine calcium, racemic ketoprofen isoleucine calcium, keto-leucine calcium, racemization hydroxyl Methionine calcium salt., Phenylalanine calcium salt., lysine acetate, histidine; The slant acidity medicine is threonine, tryptophan, tyrosine.
3. compound recipe a-keto acid sheet according to claim 1 and 2, preparation technology is:
1) above-mentioned mass fraction supplementary material is crossed 80 mesh sieves respectively;
2) with above-mentioned mass fraction keto-valine calcium, racemic ketoprofen isoleucine calcium, keto-leucine calcium, racemization hydroxyl Methionine calcium salt., Phenylalanine calcium salt., lysine acetate, histidine mixing; Add the starch of mass fraction 25-30, the cross-linked pvp of mass fraction 30-35; Further mixing gets mixture;
The PVP of mass fraction 28 is joined in the 360ml isopropyl alcohol, stir, after stirring, join in the said mixture, 20 orders are granulated, 70 ℃ of forced air dryings 2 hours, granule 1;
3) with above-mentioned mass fraction threonine, tryptophan, tyrosine mixing, add the starch of mass fraction 10-15, the cross-linked pvp of mass fraction 5-10, further mixing gets mixture;
The PVP of mass fraction 5 is joined in the 64ml isopropyl alcohol, stir, after stirring, join in the said mixture, 20 orders are granulated, 70 ℃ of forced air dryings 2 hours, granule 2;
4) granule 1,2 is mixed after, add mass fraction 10-12 Pulvis Talci, add the magnesium stearate of mass fraction 8-10, mixed pressuring plate, 60 ℃ of forced air dryings 2 hours, label, heavy according to the actual sheet of result of calculation gained, regulate sheet and weigh tabletting;
5) coating: the stomach dissolution type Opadry of mass fraction 7 is dissolved in 80% ethanol of mass fraction 93, makes coating solution, in coating pan, label is carried out coating, 60 ℃ of forced air drying half an hour, label increases weight about 3% behind the coating behind the coating;
6) detect qualified after, packing.
4. compound recipe a-keto acid sheet according to claim 1 is characterized in that: method for preparing is respectively with racemic ketoprofen isoleucine calcium, keto-leucine calcium mixing granulation under the lucifuge condition; Racemization hydroxyl Methionine calcium salt., Phenylalanine calcium salt., lysine acetate, histidine mixing granulation; Threonine, tryptophan, tyrosine mixing granulation.
5. according to claim 1 or 4 described compound recipe a-keto acid sheets, preparation technology is:
1) above-mentioned mass fraction supplementary material is crossed 80 mesh sieves respectively;
2) under the lucifuge condition, with above-mentioned mass fraction racemic ketoprofen isoleucine calcium, keto-leucine calcium mixing, add the starch of mass fraction 8-10, the cross-linked pvp of mass fraction 10-12, further mixing gets mixture;
The PVP of mass fraction 9.3 is joined in the 120ml isopropyl alcohol, stir, after stirring, join in the said mixture, 20 orders are granulated, 70 ℃ of forced air dryings 2 hours, granule 1, whole technical process requires lucifuge;
3) with above-mentioned mass fraction keto-valine calcium, racemization hydroxyl Methionine calcium salt., Phenylalanine calcium salt., lysine acetate, histidine mixing, add the starch of mass fraction 17-20, the cross-linked pvp of mass fraction 20-23, further mixing gets mixture;
The PVP of mass fraction 18.7 is joined in the 240ml isopropyl alcohol, stir, after stirring, join in the said mixture, 20 orders are granulated, 70 ℃ of forced air dryings 2 hours, granule 2;
4) with above-mentioned mass fraction threonine, tryptophan, tyrosine mixing, add the starch of mass fraction 10-15, the cross-linked pvp of mass fraction 5-10, further mixing gets mixture;
The PVP of mass fraction 5 is joined in the 64ml isopropyl alcohol, stir, after stirring, join in the said mixture, 20 orders are granulated, 70 ℃ of forced air dryings 2 hours, granule 3;
5) granule 1,2,3 is mixed after, add mass fraction 10-12 Pulvis Talci, add the magnesium stearate of mass fraction 8-10, mixed pressuring plate, 60 ℃ of forced air dryings 2 hours, label, heavy according to the actual sheet of result of calculation gained, regulate sheet and weigh tabletting;
6) coating: the stomach dissolution type Opadry of mass fraction 7 is dissolved in 80% ethanol of mass fraction 93, makes coating solution, in coating pan, label is carried out coating, 60 ℃ of forced air drying half an hour, label increases weight about 3% behind the coating behind the coating;
7) detect qualified after, packing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110437147 CN102488686B (en) | 2011-12-23 | 2011-12-23 | Compound a-keto acid tablet and preparation processes thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110437147 CN102488686B (en) | 2011-12-23 | 2011-12-23 | Compound a-keto acid tablet and preparation processes thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102488686A true CN102488686A (en) | 2012-06-13 |
| CN102488686B CN102488686B (en) | 2013-04-24 |
Family
ID=46180593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110437147 Expired - Fee Related CN102488686B (en) | 2011-12-23 | 2011-12-23 | Compound a-keto acid tablet and preparation processes thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102488686B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102961378A (en) * | 2012-11-27 | 2013-03-13 | 贵州信邦制药股份有限公司 | Compound alpha-keto acid tablets and preparation method and detection method thereof |
| CN103520156A (en) * | 2013-09-23 | 2014-01-22 | 沈阳药科大学 | Compound alpha-ketoacid tablet free of talcum powder and preparation process thereof |
| CN104607410A (en) * | 2014-12-23 | 2015-05-13 | 上海景峰制药有限公司 | Method for washing compound alpha-ketoacid tablet particles left on oven tray or oven screen |
| CN105311017A (en) * | 2014-07-06 | 2016-02-10 | 天津金耀集团有限公司 | Compound [alpha]-keto acid composition and preparation method of same |
| CN105311018A (en) * | 2014-07-06 | 2016-02-10 | 天津金耀集团有限公司 | Stable compound [alpha]-keto acid tablet composition and preparation method thereof |
| CN107549803A (en) * | 2017-09-20 | 2018-01-09 | 精晶药业股份有限公司 | A kind of effervescent tablet containing α ketone acids and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101416947A (en) * | 2007-10-23 | 2009-04-29 | 江苏信孚药业有限公司 | Compound alpha-ketoacid chewing tablet and preparation method |
| CN101773497A (en) * | 2010-02-02 | 2010-07-14 | 北京世纪博康医药科技有限公司 | Compound alpha-keto acid tablet and preparation method thereof |
| CN101991570A (en) * | 2009-08-14 | 2011-03-30 | 上海秀新臣邦医药科技有限公司 | Stable compound keto acid preparation and preparation method thereof |
-
2011
- 2011-12-23 CN CN 201110437147 patent/CN102488686B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101416947A (en) * | 2007-10-23 | 2009-04-29 | 江苏信孚药业有限公司 | Compound alpha-ketoacid chewing tablet and preparation method |
| CN101991570A (en) * | 2009-08-14 | 2011-03-30 | 上海秀新臣邦医药科技有限公司 | Stable compound keto acid preparation and preparation method thereof |
| CN101773497A (en) * | 2010-02-02 | 2010-07-14 | 北京世纪博康医药科技有限公司 | Compound alpha-keto acid tablet and preparation method thereof |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102961378A (en) * | 2012-11-27 | 2013-03-13 | 贵州信邦制药股份有限公司 | Compound alpha-keto acid tablets and preparation method and detection method thereof |
| CN102961378B (en) * | 2012-11-27 | 2016-06-01 | 贵州信邦制药股份有限公司 | A kind of compound a-ketone acid sheet and its preparation method and detection method |
| CN103520156A (en) * | 2013-09-23 | 2014-01-22 | 沈阳药科大学 | Compound alpha-ketoacid tablet free of talcum powder and preparation process thereof |
| CN103520156B (en) * | 2013-09-23 | 2015-09-30 | 沈阳药科大学 | One is not containing talcous α keto acid compound and preparation technology thereof |
| CN105311017A (en) * | 2014-07-06 | 2016-02-10 | 天津金耀集团有限公司 | Compound [alpha]-keto acid composition and preparation method of same |
| CN105311018A (en) * | 2014-07-06 | 2016-02-10 | 天津金耀集团有限公司 | Stable compound [alpha]-keto acid tablet composition and preparation method thereof |
| CN104607410A (en) * | 2014-12-23 | 2015-05-13 | 上海景峰制药有限公司 | Method for washing compound alpha-ketoacid tablet particles left on oven tray or oven screen |
| CN107549803A (en) * | 2017-09-20 | 2018-01-09 | 精晶药业股份有限公司 | A kind of effervescent tablet containing α ketone acids and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102488686B (en) | 2013-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102488686B (en) | Compound a-keto acid tablet and preparation processes thereof | |
| CN1972674B (en) | Medicament in a multilayer form | |
| CN102860987B (en) | Diclofenac sodium sustained-release capsule and preparation method thereof | |
| JP7005687B2 (en) | Pharmaceutical tablets containing levocarnitine | |
| CN101991570B (en) | Stable compound keto acid preparation and preparation method thereof | |
| CN108159011A (en) | A kind of Pregabalin stomach retention sustained-release piece of biphasic controlled release and preparation method thereof | |
| CN104688700A (en) | Readily soluble tenofovir disoproxil fumarate tablets and preparation method thereof | |
| CA2929426C (en) | Slow-release solid oral compositions | |
| CN103099873A (en) | Green coffee bean extract sustained-release tablet and preparation method thereof | |
| CN102552871B (en) | A kind of tannalbin yeast chewable tablet and production method thereof | |
| CN104434826A (en) | Rosuvastatin calcium dispersible tablet | |
| JP2020511534A (en) | Glucose pellet, method for producing the same, and use thereof | |
| CN110664772A (en) | Sevelamer carbonate tablet and preparation method thereof | |
| KR20150059720A (en) | Anagliptin－containing preparation | |
| KR101559339B1 (en) | Fast-release tablet comprising high amounts of herbal substances | |
| CN105769773A (en) | Loxoprofen sodium sustained-release pellet | |
| KR20170119651A (en) | High-loading, controlled-release magnesium oral dosage forms and methods for making and using same | |
| CN102526080A (en) | Medicinal composition and tablet containing salicylic acid methyl ester lactoside and preparation methods thereof | |
| CN105726503A (en) | Levofloxacin hydrochloride tablet | |
| CN105769796B (en) | A kind of pharmaceutical preparation and preparation method thereof containing vildagliptin and Metformin hydrochloride | |
| CN106176649B (en) | Folic acid VB12 tablet and preparation method thereof | |
| CN103284973A (en) | Adefovir dipivoxil composition and preparation method thereof | |
| CN103550182A (en) | Enteric-coated sustained release composition | |
| CN110604726B (en) | Sofosbuvir composition and application thereof | |
| CN103271908B (en) | Oral tablet and preparation method thereof containing Telmisartan and Amlodipine Besylate Tablet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130424 Termination date: 20211223 |